A Phase 3 interventional study of Erythropoietin + Probiotic and EPO in Anaemia, Chronic Kidney Disease and Regular Hemodialysis, sponsored by Badr University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Badr University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing erythropoietin in Anemia — 2 open to participants now, 2 under way, 1 of them phase 3. Erythropoietin · Anemia.
Among the 23 studies testing erythropoietin in Anemia, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 11 in phase 3, and was the 23rd registered.
1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.
Browse Anemia studies →2 of the 23 studies testing erythropoietin in Anemia are open now, in 1 country. Recruiting first, the newest first:
Federal University of São Paulo · Sites in Brazil
Ages 18–80 · Healthy volunteers
Blau Farmaceutica S.A.
Ages 2–17
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 11 · Phase 4 5
First in 1998; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 117 across 1,338 interventional studies indexed under Anemia.
Median enrollment 104 across the 21 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Badr University is the lead sponsor of 64 studies on the registry; 18 are open to participants now.
Badr University has 1 study filed under Anemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing erythropoietin in Anemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are:
Can probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients.
Participants will:
Take Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EPO (4000 IU) + Probiotic
Drug: Erythropoietin + Probiotic
Erythropoietin (Epoetin 4000 IU)
Drug: EPO
Drug pages: ErythropoietinStudies of ErythropoietinErythropoietin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ProbioticStudies of ProbioticProbiotic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Anaemic chronic kidney disease patients on regular hemodialysis treated with Erythropoietin + Probiotic
Anaemic chronic kidney disease patients on regular hemodialysis treated with Erythropoietin
- Hemoglobin concentration
\- Hemoglobin concentration (g/dL)at 2 weeks, and 3-months postintervention
Time frame: at baseline, and 3-months postintervention
- Erythropoietin resistance index (ERI)
\- ERI = (ESA dose per week) / (body weight) / (hemoglobin level).
Time frame: at baseline, and 3-months postintervention
Serum creatine
mg/dl
Time frame: at baseline, and monthly (after 1,2,3 moths)
Urea Reduction Ratio
Time frame: at baseline, and monthly (after 1,2,3 moths)
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Aug 2026, 6 months.
Of 50 non-industry phase 3 interventional studies under Anemia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 6 months is below that.
Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Dec 2025 → Feb 2026, primary completion Mar 2026 → Aug 2026 and completion May 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Erythropoietin · Probiotic
Badr University